ALK and hypertriglyceridemia: Lorlatinib has a unique treatment-related adverse event profile compared with other ALK-TKIs that is characterized by the frequent incidence of hypercholesteremia and hypertriglyceridemia, which have been found to occur in 61% and 82% of lorlatinib-treated patients included in a pooled safety analysis (n = 295) [14,15].